Table 5.
Association of PSRC1, CELSR2, and SORT1 SNPs with Warfarin Sensitivity During the Initiation Phase of Therapy of 212 Cardiovascular Patients Treated with Warfarin
| Gene | SNP ID | Genotype | Sensitivea (n= 32) | Moderateb (n= 146) | Resistancec (n= 34) | Overall P-value* |
|---|---|---|---|---|---|---|
| PSRC1 | rs646776 | CC | (0/11) 0.0% | (8/11) 72.7% | (3/11) 27.3% | 0.028 |
| P-value* | 0.15 | 0.78 | 0.3 | |||
| CT | (16/61) 26.6% | (39/61) 63.9% | (6/61) 9.8% | |||
| P-value* | 0.004 | 0.32 | 0.12 | |||
| TT | (16/140) 11.4% | (99/140) 70.7% | (25/140) 17.9% | |||
| P-value* | 0.04 | 0.42 | 0.31 | |||
| CELSR2 | rs660240 | CC | (17/139) 12.2% | (97/139) 69.8% | (25/139) 18% | 0.062 |
| P-value* | 0.12 | 0.02 | 0.15 | |||
| TC | (14/58) 24.1% | (39/58) 67.2% | (5/58) 8.6% | |||
| P-value* | 0.81 | 0.7 | 0.8 | |||
| TT | (0/11) 0.0% | (8/11) 72.7% | (3/11) 27.3% | |||
| P-value* | 0.23 | 0.08 | 0.29 | |||
| rs12740374 | GG | (16/145) 11% | (102/145) 70.3% | (27/145) 18.6% | 0.013 | |
| P-value* | 0.03 | 0.004 | 0.2 | |||
| GT | (15/57) 26.3% | (38/57) 66.7% | (4/57) 7% | |||
| P-value* | 0.59 | 0.63 | 0.86 | |||
| TT | (0/9) 0.0% | (6/9) 66.7% | (3/9) 33.3% | |||
| P-value* | 0.14 | 0.03 | 0.15 | |||
| SORT1 | rs602633 | GG | (16/131) 12.2% | (93/131) 71% | (22/131) 16.8% | 0.29 |
| P-value* | 0.13 | 0.37 | 0.75 | |||
| GT | (15/65) 23.1% | (41/65) 63.1% | (9/65) 13.8% | |||
| P-value* | 0.04 | 0.24 | 0.53 | |||
| TT | (1/15) 6.7% | (11/15) 73.3% | (3/15) 20% | |||
| P-value* | 0.32 | 0.65 | 0.65 |
Notes: *Chi-square test with p< 0.05 is considered significant. aWarfarin sensitive group (required minimum warfarin dose < 21 mg/week). b.Warfarin moderate response group (required average warfarin dose between 21 and 49 mg/week). cWarfarin resistance group (required high warfarin dose > 49 mg/week).